Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBT Margin (2016 - 2025)

Historic EBT Margin for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to 69.79%.

  • Aytu Biopharma's EBT Margin fell 721500.0% to 69.79% in Q4 2025 from the same period last year, while for Dec 2025 it was 38.7%, marking a year-over-year decrease of 347600.0%. This contributed to the annual value of 20.71% for FY2025, which is 47800.0% down from last year.
  • As of Q4 2025, Aytu Biopharma's EBT Margin stood at 69.79%, which was down 721500.0% from 14.15% recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's EBT Margin peaked at 20.69% during Q1 2025, and registered a low of 220.22% during Q1 2022.
  • In the last 5 years, Aytu Biopharma's EBT Margin had a median value of 28.57% in 2022 and averaged 50.46%.
  • Per our database at Business Quant, Aytu Biopharma's EBT Margin tumbled by -1234500bps in 2021 and then surged by 1885500bps in 2023.
  • Quarter analysis of 5 years shows Aytu Biopharma's EBT Margin stood at 49.95% in 2021, then surged by 49bps to 25.47% in 2022, then surged by 129bps to 7.46% in 2023, then crashed by -68bps to 2.35% in 2024, then crashed by -3064bps to 69.79% in 2025.
  • Its last three reported values are 69.79% in Q4 2025, 14.15% for Q3 2025, and 128.46% during Q2 2025.